Osimertinib Mesylate from Japan
Osimertinib mesylate is a third-generation EGFR TKI for lung cancer with T790M mutation. The indoline-quinazoline structure qualifies as aromatic modified heterocyclic drug under HTS 2933.99.75.00.
Duty Rate — Japan → United States
6.5%
Rate breakdown
9903.03.030%Articles the product of any country, as provided for in subdivision (aa)(ii) of U.S. note 2 to this subchapter
Import Tips
• Include polymorphic form designation (Form A) in import documentation
• Particle size distribution critical for bioavailability - include laser diffraction data
• Declare therapeutic class on entry summary to facilitate FDA review